N4 Pharma Grants 15 Million Options to Key Directors

N4 Pharma (GB:N4P) has released an update.

N4 Pharma has granted 15 million options over ordinary shares to key directors, including CEO Nigel Theobold and Executive Director Luke Cairns, at an exercise price of 0.75p. These options, part of the company’s strategy to align leadership incentives with long-term growth, will vest in equal tranches over three years. This move underscores N4 Pharma’s commitment to advancing its innovative delivery systems for cancer treatments and vaccines.

For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.